Acrivon Therapeutics

PhD biochemist educates on science behind biotech investments, emphasizing due diligence to avoid pitfalls. Analyst holds no positions in mentioned companies and receives no compensation beyond Seeking Alpha. Seeking Alpha's disclosure notes past performance's irrelevance to future results and the platform's non-licensed status.

Acrivon Therapeutics, with a $214M market cap, develops precision oncology drugs using its AP3 platform. ACR-368, its lead candidate, shows 63% ORR in endometrial cancer. The AP3 platform identifies kinase interactions, potentially enhancing drug efficacy. ACR-2316, a dual WEE1/PKMYT1 inhibitor, shows promising preclinical data. Acrivon's strong cash position funds operations into 2026, though it faces competitive and regulatory challenges.

HC Wainwright lowered FY2024 EPS estimates for Acrivon Therapeutics to ($2.45) from ($2.31), maintaining a 'Buy' rating and $22.00 price target. Other analysts also issued reports, resulting in a consensus 'Buy' rating and average target price of $23.67. Acrivon Therapeutics' stock opened at $6.96, with a market cap of $216.73 million.

Acrivon Therapeutics granted 61,950 stock options to employees under its 2023 Inducement Plan, with 25% vesting after one year and 2.083% monthly thereafter. The company develops precision oncology drugs using its AP3 platform, with lead candidate ACR-368 targeting CHK1/CHK2 in a Phase 2 trial. The FDA has granted Fast Track and Breakthrough Device designations for ACR-368. Acrivon reported positive clinical data for ovarian and endometrial cancers, with a 62.5% response rate in endometrial cancer.

Acrivon Therapeutics initiates Phase 1 trial for ACR-2316, a novel cancer treatment targeting WEE1/PKMYT1 via AP3 platform, with first patient dosed. Trial aims to assess safety, tolerability, and optimal dosage, with initial results expected in H2 2025.

Acrivon Therapeutics announced the first patient dosed in its Phase 1 trial for ACR-2316, a potent, selective WEE1/PKMYT1 inhibitor designed by its AP3 platform to deliver complete tumor regression. The trial aims to assess safety, tolerability, and pharmacokinetic profile, with initial clinical data expected in 2H 2025.

Acrivon Therapeutics reports 62.5% response rate for ACR-368 in endometrial cancer patients, with no median duration reached at 6 months. FDA clears ACR-2316 for Phase 1 trials, starting Q4 2024. Company has funds until H2 2026, driven by AP3 Interactome platform.

Acrivon Therapeutics reports 62.5% confirmed ORR in OncoSignature-positive endometrial cancer patients from ACR-368 Phase 2 trial, with significant responder segregation (p=0.009) and median duration of response not yet reached (~6 months). FDA clears IND for ACR-2316, with first-in-human dosing expected Q4 2024. AP3 Interactome platform generates proprietary insights for drug development.

Piper Sandler reissued a 'buy' rating on Acrivon Therapeutics (NASDAQ:ACRV) with a $30.00 target, indicating a 271.29% potential upside. Other analysts also maintain positive ratings, resulting in a 'Moderate Buy' consensus. The stock opened at $8.08, with a market cap of $249.49 million. Institutional investors increased their holdings, with 71.62% ownership. Acrivon Therapeutics focuses on developing oncology medicines using its precision medicine platform.